Turning back the clock on fibrosis

Small molecule inhibitors for reversal of fibrosis

First in class novel inhibitors targeting a central pathway in fibrosis and inflammation

Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function.

 

Inosi’s technology is based on collaborative research from the founding team at Monash University, the Monash Biomedicine Discovery Institute ,and the Monash Institute of Pharmaceutical Sciences.

IP Group helped spin-out the company and provided seed investment.

Our Partners

IP Group Logo
Monash_Logo_white_900ppi.png

Fibrosis is a global problem with high unmet need

45%

deaths linked to fibrosis

10%

of the population have a fibrotic condition

0

drugs able to reverse fibrosis